Upstream Bio Statistics
Total Valuation
Upstream Bio has a market cap or net worth of $377.13 million. The enterprise value is $71.69 million.
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Upstream Bio has 54.42 million shares outstanding. The number of shares has increased by 105.15% in one year.
| Current Share Class | 54.42M |
| Shares Outstanding | 54.42M |
| Shares Change (YoY) | +105.15% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | 66.86% |
| Float | 35.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 109.92 |
| Forward PS | 231.74 |
| PB Ratio | 1.21 |
| P/TBV Ratio | 1.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.14, with a Debt / Equity ratio of 0.00.
| Current Ratio | 23.14 |
| Quick Ratio | 21.74 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -41.83% and return on invested capital (ROIC) is -28.57%.
| Return on Equity (ROE) | -41.83% |
| Return on Assets (ROA) | -27.76% |
| Return on Invested Capital (ROIC) | -28.57% |
| Return on Capital Employed (ROCE) | -56.50% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $44,293 |
| Profits Per Employee | -$2.09M |
| Employee Count | 75 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.05% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -36.05% |
| 50-Day Moving Average | 8.06 |
| 200-Day Moving Average | 17.21 |
| Relative Strength Index (RSI) | 48.51 |
| Average Volume (20 Days) | 727,583 |
Short Selling Information
The latest short interest is 3.90 million, so 7.16% of the outstanding shares have been sold short.
| Short Interest | 3.90M |
| Short Previous Month | 3.64M |
| Short % of Shares Out | 7.16% |
| Short % of Float | 11.13% |
| Short Ratio (days to cover) | 5.94 |
Income Statement
In the last 12 months, Upstream Bio had revenue of $3.32 million and -$156.76 million in losses. Loss per share was -$2.90.
| Revenue | 3.32M |
| Gross Profit | 3.32M |
| Operating Income | -171.96M |
| Pretax Income | -156.76M |
| Net Income | -156.76M |
| EBITDA | -171.77M |
| EBIT | -171.96M |
| Loss Per Share | -$2.90 |
Full Income Statement Balance Sheet
The company has $294.58 million in cash and $1.11 million in debt, giving a net cash position of $293.47 million or $5.39 per share.
| Cash & Cash Equivalents | 294.58M |
| Total Debt | 1.11M |
| Net Cash | 293.47M |
| Net Cash Per Share | $5.39 |
| Equity (Book Value) | 304.00M |
| Book Value Per Share | 5.59 |
| Working Capital | 302.61M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$139.96 million and capital expenditures -$165,000, giving a free cash flow of -$140.13 million.
| Operating Cash Flow | -139.96M |
| Capital Expenditures | -165,000 |
| Depreciation & Amortization | 194,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -140.13M |
| FCF Per Share | -$2.57 |
Full Cash Flow Statement Margins
| Gross Margin | 100.00% |
| Operating Margin | -5,176.49% |
| Pretax Margin | -4,718.96% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Upstream Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -105.15% |
| Shareholder Yield | -105.15% |
| Earnings Yield | -42.93% |
| FCF Yield | -38.37% |
Analyst Forecast
The average price target for Upstream Bio is $38.25, which is 451.95% higher than the current price. The consensus rating is "Buy".
| Price Target | $38.25 |
| Price Target Difference | 451.95% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 12.12% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Upstream Bio has an Altman Z-Score of 36.77 and a Piotroski F-Score of 1.
| Altman Z-Score | 36.77 |
| Piotroski F-Score | 1 |